Cardinal Health, Inc. 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Cardinal Health, Inc., covering the three-month period ended September 30, 1997. The company operates primarily in the wholesale distribution of pharmaceuticals (91% of revenues) and healthcare services, including pharmacy franchising, automation, and management.
Key Financial Metrics
| Metric | Q1 1998 (Sep 30, 1997) | Q1 1997 (Sep 30, 1996) |
|---|---|---|
| Net Revenues | $2,869,971,000 | $2,535,476,000 |
| Gross Margin | $222,465,000 (7.75%) | $197,128,000 (7.77%) |
| Operating Earnings | $88,945,000 | $72,972,000 |
| Net Earnings | $54,230,000 | $41,401,000 |
| Earnings Per Share (Diluted) | $0.49 | $0.39 |
| Cash and Equivalents | $180,515,000 | $125,119,000 |
| Working Capital | $1,158,000,000 | $1,095,000,000 (Jun 30, 1997) |
| Long-Term Obligations | $277,882,000 | $277,766,000 (Jun 30, 1997) |
Cash Flow: Net cash used in operating activities was $48.2 million, compared to $180.5 million in the prior year. This improvement was driven by better asset management and reduced cash usage for inventory relative to the prior period, though inventory levels still increased by $174.5 million.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 13% year-over-year. Distribution businesses grew 11%, while Service businesses grew 46%.
- Margin Stability: Gross margin percentage remained stable at 7.75%, despite a decline in Distribution margins (5.69% to 5.43%) due to competitive pricing. This was offset by a higher mix of higher-margin Service revenues.
- Expense Efficiency: Selling, general, and administrative (SG&A) expenses as a percentage of revenue improved to 4.65% from 4.89%, reflecting economies of scale and productivity gains.
- Interest Expense: Interest expense decreased by $1.6 million due to the extinguishment of $100 million in 8% Notes in March 1997.
Guidance, Outlook, and Risks
Mergers and Acquisitions:
- MediQual Systems, Inc.: Agreed to a stock-for-stock merger expected to complete by January 31, 1998. Cardinal will issue approximately 0.6 million shares.
- Bergen Brunswig Corporation: Agreed to a stock-for-stock merger expected to complete by the end of fiscal Q3 1998. Cardinal will issue approximately 40 million shares and assume $418 million in long-term debt.
Legal Proceedings: The company is a defendant in consolidated antitrust litigation regarding brand name prescription drug pricing. A Court of Appeals reversed a summary judgment in favor of the defendants in August 1997. Cardinal plans to seek review by the U.S. Supreme Court. The company believes the allegations are without merit and does not expect a material adverse effect on financial statements.
Year 2000 Compliance: The company is assessing and correcting systems for Year 2000 compliance, expecting substantial completion by the end of calendar 1998. Costs are not anticipated to have a material adverse effect.
Investor Verification Checklist
- Verify the status and regulatory approval timeline for the Bergen Brunswig merger, specifically the assumption of $418 million in debt.
- Monitor the outcome of the Supreme Court petition regarding the Brand Name Prescription Drug Litigation.
- Assess the impact of the 40 million new shares to be issued for the Bergen merger on future earnings per share dilution.
- Review the sustainability of the 46% growth rate in the Service business segment.
- Confirm the timeline and cost estimates for Year 2000 system compliance.